2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1739

Vδ1, Vδ2, and Other γδT Cells in Blood and Synovium of Rheumatoid Arthritis and Other Autoimmune Arthritides
Abstract Number: 1740

Fc-Derived Immunodominant Peptides Stimulate Natural Regulatory T Cells: A New Avenue to Overcome Defects in the Fc Antigen Processing and Restore Immune Regulation in Rheumatic Diseases
Abstract Number: 1741

Tolerance and Efficiency of Anti-Programmed Death 1 Antibodies in Patients with Cancer and Preexisting Autoimmune or Inflammatory Diseases
Abstract Number: 1742

Involvement of T Helper 17 Cells in Inflammatory Arthritis Depends on the Host Intestinal Microbiota
Abstract Number: 1743

Serine Arginine/Rich Splicing Factor 1 (SRSF1) Increases IL-2 Production in T Cells By Increasing the Expression of NFAT and c-Fos
Abstract Number: 1744

Transciptome Profile of Inflammation Inducted Circulating Effector and Regulatory T Cells Is Dominated By HLA-DR Pivoted Functional Networks in Active Juvenile Idiopathic Arthritis Patients
Abstract Number: 1745

Autophagic Memory in Stress Experienced Human T Cells
Abstract Number: 1746

mTOR Pathway Activation in Takayasu Arteriti
Abstract Number: 1747

Human C-C Chemokine Receptor-6 (CCR6)+ Th Memory Cells, Including Th17 and Th17.1 Cells, Change into Anti-Inflammatory Cells with Regulatory Capacity upon Exposure to Vitamin D
Abstract Number: 1748

Cbl-b Associates with Bcl-6 and Is Differentially Expressed in Circulating Follicular T Helper Cells of Patients with Systemic Lupus Erythematosus
Abstract Number: 1749

The Epidemiology of ANCA Associated Vasculitis in the U.S.: A 20 Year Population Based Study
Abstract Number: 1750

Risk of Cardiovascular and Thrombotic Disease Among Patients with Incident ANCA-Associated Vasculitis: A 20 Year Population Based Cohort Study
Abstract Number: 1751

Association of a TNFSF4 Upstream Region Single Nucleotide Polymorphism with Susceptibility to Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Abstract Number: 1752

Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis
Abstract Number: 1753

“Recurrent Venous Thromboembolic Events in Granulomatosis with Polyangiitis Patients”

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].